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 Recent advances in pancreas organogenesis greatly improved the understanding of 
cell lineage from inner cell mass to fully differentiated -cells. Upon such knowledge, 
insulin-producing cells similar to -cell to certain extent are generated from various 
cell sources including embryonic stem cells (ESCs) and induced plurimotent stem (iPS) 
cells, although fully differentiated cells comparable to -cell are not yet available. 
Bioartificial pancreas is a therapeutic approach to enable allo- and 
xeno-transplantation of islets without immune. Among several types of bioartificial 
pancreas, micro-encapsulated porcine islets are already used in clinical trials and, 
perhaps, replace islet transplantation in the near future. Some types of bioartificial 
pancreas such as macro-encapsulation are also useful to keep transplanted cells to be 
enclosed for possible need of retrieval. Therefore, early clinical applications of 
artificially generated -like cells, especially those from ESCs or iPS cells, will be 
considered in combination of retrievable BAP.  
 
Introduction 
 Diabetes mellitus (DM) is a heterogenous metabolic disease that is eventually 
attributed to insulin deficiency, which is especially true in type 1 diabetes mellitus 
(T1DM) in which insulin producing -cells residing in islets of Langerhans of the 
pancreas are primarily destroyed by autoimmune response or other unknown causes. 
Therefore, patients of T1DM need insulin replacement or endogenous -cell 
reconstruction if exogenous insulin cannot maintain proper blood glucose control. The 
latter is currently achieved only by either pancreas or islet transplantation. However, 
these transplantation therapies share common problems of donor scarcity and adverse 
effects of immune suppression.  
 The number of people suffering from DM in the world is estimated to be 285 million in 
2010 and to become 439 million in 2030 1. This estimation and many other predictions 
are warning about the possibility that increasing number of DM patients will cause 
serious socio-economical burden unless effective and efficient therapies are developed 
for cure and prevention of DM.  
 Regenerative medicine is the process of creating living, functional tissues to repair or 
replace tissue or organ function lost due to age, disease, damage, or congenital defects 2. 
In DM, especially in T1DM, what is lost is -cell function. Therefore, regenerative 
medicine for DM is to create endogenous -cell function. Toward this end, many 
possible approaches, ranging from in situ regeneration of islet of Langerhans to 
mechanical artificial pancreas 3, are explored. Among these approaches, remarkable 
advancements in ex vivo creation of cells with -cell-like function (-like cells) from 
various cell sources are recently achieved and, with great expectations, may lead to 
cellular therapy for T1DM. This article will briefly review these advancements. And 
then, recent state of bio-artificial pancreas (BAP) will be also reviewed, since BAP that 
enables cell transplantation without immune suppression should be an essential 
technology for ideal cellular therapy using ex vivo created -like cells.  
 
In vivo differentiation and growth of -cell 
 Studies in developmental biology, using knockout animals and lineage tracing, have 
revealed how -cell develops in vivo. Several important steps are summarized in Figure 
1, which was modified from a figure in our old review article 4. In these, pancreatic and 
duodenal homeobox-1 (Pdx1, also known as IPF1, STF1, and IDX1) is a master gene for 
the pancreas, since Pdx1-ko mice lack the pancreas, and also an important 
transcription factor for insulin 5. Neurogenin 3 (Ngn3, also known as Math4B and 
Atoh5) is an essential transcription factor for pancreatic endocrine cells. Ngn3-positive 
and hormone-negative cells, although such cells were hardly observed in adult animals, 
were observed within or adjacent to pancreatic ducts in embryonic stages, and 
considered to be a common progenitor of all islet cells 6,7. Recently, Ngn3-positive cells 
were found and isolated in partial duct ligation model of adult mice 8, suggesting islet 
neogenesis in adult pancreas as discussed later. In addition to Pdx1, other factors 
including MafA and Nkx2.2 play important roles in expression of -cell-specific genes 
as well as insulin. Therefore, these transcription factors are important to maintain  
cell function 9.  
 Islet tissue shows approx. 20-fold growth after birth in rodents and humans, and it 
also shows additional compensatory growth in response to increased demand, e.g. 
obesity and pregnancy 10. In addition, significant pancreatic regeneration occurs after 
major pancreatectomy (Px) 11, 12 and some types of injury in rodents.  
 Until recently, there was a long discussion about which cells are responsible for the 
growth and regeneration of islets and, more fundamentally, whether formation of new 
islets (neogenesis) really occurs or not. However, recent lineage tracing experiments 
are expected to put an end to this discussion. Dor et al. generated a transgenic mouse 
strain in which insulin promoter drives the expression of tamoxifen-dependent Cre 
recombinase and, further, Cre activates a reporter gene. Thus, in this mouse, reporter 
gene is only expressed in insulin-expressing cells present at the pulse of tamoxifen, as 
well as their progeny. They have shown that all -cells at the observation time point 
used to be or progeny of -cells present at the tamoxifen injection, suggesting that 
adult pancreatic -cells are formed by self-duplication (replication) in normal life-time 
and even after minor (70%) Px 13. On the other hand, as mentioned above, Xu et al. 
have found Ngn3-positive cells in ductal lining of adult injured pancreas and shown 
that these cells can become islet cells both in situ and in vitro 8. In addition, 
Bonner-Weir and her colleagues performed duct-specific lineage tracing experiments 
using carbonic anhydrase II (CAII) as a marker to test their hypothesis that mature 
duct epithelial cells are pancreatic progenitor. Their results show that formation of 
both new islets and newly differentiated acini from CAII-expressing ductal progenitors 
occurs during neonatal period 14, 15 and that substantial number of islets are genetically 
marked in duct ligated pancreatic lobe 14. Acinar cell-specific lineage tracing of similar 
technique have been reported 16, 17. According to these reports, acinar cells contribute to 
metaplastic duct formation in pancreatitis models but do not become a -cell after Px, 
exendin-4 treatment, duct ligation, or chemical pancreatitis. Taken together, new 
-cells seem to be formed in adult pancreas either through replication of pre-existing 
-cells or islet neogenesis from duct epithelial cells depending on circumstances, but 
not from acinar calls (Fig 2). Very recently, Solar et al. expressed their negative view for 
islet neogenesis from the duct in their report dealing with Hnfpositive cells that 
appear early in pancreatogenesis and gradually restrained during gestation 18. 
Therefore, neogenesis issue may need to be discussed a little longer until its 
settlement.  
 
Various cell sources for -like cells 
 In vitro treatments can induce insulin-producing cells from wide range of cell sources. 
A number of reports have indicated that insulin-producing cells similar to -cell to 
certain extent can be induced in various type of adult cells derived from bone marrow 19, 
umbilical cord blood 20, liver 21, intestine 22, and so on 4, 23, after introduction of 
pancreatic lineage-related genes such as Pdx1. Protein transduction is another method 
to change cell fate as well as cell function. Protein transduction of Pdx1, 
BETA2/NeuroD and other factors are shown to enhance differentiation to -cell 24. In 
addition to adult stem cells, Wei et al 25 showed that human amniotic epithelial cells 
can produce insulin mRNA under nicotinamide stimulation in vitro and can produce 
human insulin in several weeks when implanted in streptozotocin-diabetic mice. These 
studies indicate that various cell types can be used for generate -like cells, although 
these generated cells are not so mature as -cell in most cases and there remains safety 
concern if they are gene-engineered.  
 
 Pancreas-derived cells are other cell sources since exocrine pancreatic tissue is a waist 
after islet isolation for transplantation. Ramiya et al. 26 have reported that pancreatic 
duct epithelial cells obtained from adult non-obese diabetic (NOD) mice can 
continuously produce islet-like cell clusters after long term culture and that 
hyperglycemia can be controlled by transplantation of these clusters. Following this, 
similar in vitro generation of -like cells from cultured duct-like cells has been reported 
from several other groups (please refer to the other reviews 27, 28. In addition, this 
differentiation is shown to be mediated, at least partly, through phosphatidylinositol-3 
kinase-related pathway 29.  
 As mentioned earlier, acinar cells are shown not to contribute to endocrine cell growth 
in vivo, but they are shown to generate -like cells in vitro through formation of cell 
cluster in suspension culture 30. Furthermore, recent report showed that exocrine cells 
can be directly converted to -cells in vivo by introducing three transcription factors, 
Pdx1, Ngn3 and MafA 31. In addition to duct and acinar cells, cells showing less 
differentiated fibroblast-like appearance can be cultured from pancreatic tissue. 
Baertschiger et al. showed that these highly proliferative cells express transcription 
factors implicated to -cell development as well as several mesenchymal stem cell 
(MSC)-specific markers, yet it is not clear whether these cells can re-differentiate to 
-like cells 32. Taken together, pancreatic duct-like cells, and even acinar cells, seem 
potential source for -like cells, although the details of these phenomena are mostly 
unknown and, in general, the growth of these cells is slow. In this aspect, MSC-like 
cells from the pancreas, with high proliferative ability, may be another candidate.  
 
 Embryonic stem cell (ESC) is an attractive cell source for any kind of cell therapies, 
because they proliferate almost indefinitely and has very wide differentiation potency 
(pluripotency).  Since the establishment of ESC 33, 34, many groups have studied -cell 
differentiation form ESC. In earlier attempts of Lumelsky et al. 35 and many other 
groups including ours 36, insulin-producing cell clusters were generated through 
nestin-positive cells by step-wise procedures somewhat similar to ones for neural cell 
differentiation. However, these cells can hardly be regarded as -like cells after the 
report by Rajagopal et al. 37, in which insulin-positive cells were shown to result mostly 
by insulin up-take from the culture medium. It is known that several types of 
insulin-producing cells other than -cell appear in certain neuronal cell, yolk sac and 
liver during embryonic development 38. Therefore, insulin staining and mRNA 
expression in these early studies are now considered to be attributed mostly to 
differentiation toward neuron-like cells or extra-embryonic endoderm 39, although our 
study showed insulin granules by electron microscope, mRNA expression of pancreatic 
genes such as glucagon and amylase as well as insulin and, further, significant 
decrease in blood glucose after transplantation to diabetic mice 36. Anyway, lessons 
from these earlier attempts emphasize the importance of understanding developmental 
biology about pancreas and -cell.  
 Assady et al. reported generation of insulin-secreting cells from ESC after 
spontaneous differentiation, although the number of such cells and insulin content in 
them was low 40. However, their study clearly showed the possibility that -like cells 
can be generated from ESC, and subsequent studies employed strategies that closely 
follow the differentiation steps toward -cell during embryogenesis, namely ESC 
definitive endoderm, primitive gut tube, posterior foregut, pancreatic endoderm, 
endocrine presursor and finally islet of Langerhans. Following these multiple steps, 
D’Amour et al. generated cells that release C-peptide in response to multiple secretory 
stimuli from human ESCs, but they were only minimally responsive to glucose 41. 
Therefore, their methods still need some steps that induce final differentiation of 
-cells, e.g. second wave expression of Pdx1 and MafA expression. In the sasme line of 
study, Kroon et al. recently reported that pancreatic endoderm derived from human 
embryonic stem (hES) cells efficiently generates glucose-responsive endocrine cells 
after implantation into mice 42. In this study, pancreatic endoderm-like tissue that 
contains few hormone-expressing cells was generated in vitro and then transplanted 
into epididymal fat pad to allow further development in vivo. Then, the graft became 
fully responsive to glucose 3 months after transplantation. So far, the factors that 
induce final -cell differentiation are unknown, but may be simply time longer than 
allowed for the in vitro protocols, or difficult to reproduce in vitro, such as 
vascularization and the interaction with adjacent tissues 43. Several other groups also 
reported in vitro differentiation of -like cells from human ESCs, through definitive 
endoderm with distinct methods 44, 45.  
 Induced pluripotent stem (iPS) cell 46 is an artificial cell type that is generated from 
somatic cells to mimic ESC. Human iPS cells avoid the ethical difficulties regarding the 
use of human embryos and tissue rejection following transplantation if they are 
generated from patients’ own cells. The protocols used in humsn ESCs, iPS cells are 
also shown to differentiate into -like cells in vitro 47, 48. ESC and iPS cells are potential 
and indefinite cell source for cell therapies. However, further studies are needed 
toward the final differentiation of -like cells as well as to establish acceptable safety 
until clinical usage.  
 
Bioartificial pancreas  
 The original concept of BAP is to enable islet transplantation without immune 
suppression by protecting islets with semipermeable barrier against immune rejection 
(Fig 3). BAP can be used not only allotransplantation but also xenotransplantation of 
the islets depending on the immuno-isolation property of the barrier. 
 As described above, artificial generation of -like cells are intensely investigated. If 
any of these studies reach the end to supply sufficient amount of -like cells of 
sufficient quality, transplantation of these cells, as well as human islets, will be 
regarded as a possible treatment for T1DM. However, one major difficulty in this 
approach is that the transplanted cells are exposed to the patient's inflammatory and 
autoimmune environment, which originally destroyed their own -cells. Therefore, 
even if a good source of -like cells can be identified for transplantation therapy, these 
cells need to be protected against these destructive influences. Therefore, BAP is 
expected to play an important role in future cellular therapy for T1DM.  
 BAP can be classified into several types, namely diffusion chamber, blood perfusion 
and encapsulation types (Fig. 4). Each type has its advantages and drawbacks as 
described below. 
 In diffusion chamber type, islets are contained in the space surrounded by 
semipermeable membrane. Typically, islets are contained between two semipermeable 
membranes placed on both side of ring-like structure 49. In addition, islets placed in 
hollow fibers can be regarded as a particular type of this kind. The structure of this 
type is rather simple and you can choose optimal membrane with desired pore size. On 
the other hand, islets tend to clump each other and undergo central necrosis. To place 
islets with some types of hydrogel such as agarose can avoid this clumping and improve 
BAP function 50. Our group has developed mesh-reinforced polyvinyl alcohol (PVA) tube 
and bag of this type 51. Recently, Yang et al. developed a chamber implantable to bone 
marrow cavity using calcium phosphate cement as immunoisolative device to enclose 
insulinoma/agarose microspheres 52 and reported therapeutic used of this to 
spontaneously diabetic cat 53.  
 Blood perfusion type is similar to dialysis device. Blood is perfused in the hollow fiber 
and islets are placed around the fibers. The advantage of this type is high diffusive 
exchange rate, however this type is hardly implantable in a body and needs some 
anticoagulation treatment. Ikeda et al. developed BAP of this type and showed its 
effect in pancreatectomized pigs 54.  
 Encapsulation type can be divided in to two categories, namely micro-encapsulation 
and macro-encapsulation. In micro-encapsulation, one or a few islets are encapsulated 
in hydrogel, such as alginate, like micro-beads. This type is favorable for substance 
exchange because of its large surface area. However, this type is hardly retrievable 
once they are implanted into the body, for example abdominal cavity. Most famous 
example of this type is DIABECELL®, a product of a bio-venture company, Living Cell 
Technologies 55, 56. It is a porcine insulin-producing cell micro-encapsulated in alginate 
hydrogel. Micro-beads are implanted into the abdominal cavity of the patients without 
any immune suppretion. According to their announcement on the internet, Phase I and 
II clinical trials are now ongoing in Russia and New Zealand.  And, so far, beneficial 
effects, such as reduced HbA1c levels and/or reduced insulin doses including insulin 
independence are observed without serious adverse effects. Therefore, their clinical 
trials are showing promising capability of micro-encapulated islets. However, 
micro-beads implanted in the abdominal cavity are not retrievable. So, this method will 
not be suitable for the early application of artificially generated -like cells unless 
safety of such cells become proven at high levels.  
 In contrast to micro-encapsulation, macro-encapsulation encloses islets in a lager 
hydrogel that can be handled macroscopically. Therefore, macro-encapsulated islets are 
easy to retrieve and seemingly suitable for early use of artificially generated -like cells, 
because it can be retrieved if any kind of adverse events such as tumor formation. Our 
group developed macro-encapsulated islets using agarose-based hydrogel and showed 
the effect in xenotransplantation into prevascularized subcutaneous site 57, 58. Another 
example of this type of BAP is PVA-macro-encapsulated islets. We developed this 
device through combination of cryo-preservation methods of islets and hydrogel  
formation from PVA aqueous solution by freezing and thawing 59. Implantation of this 
BAP was show to prevent renal dysfunction observed in severely diabetic mice, 
suggesting reconstruction of basal insulin secretion by BAP is really effective to 
prevent diabetic complications, at least to certain extent 60.  
 Conclusions and prospective 
 Recent advances in the study of pancreatic organogenesis revealed cell lineage of 
-cells and important steps from inner cell mass from which ESCs are established to 
fully differentiated -cells. Understanding these informations is important to establish 
efficient protocol of -cell differentiation from other cell types, especially from ESCs 
and iPS cells. -like cells can be generated from various cell sources with/without gene 
transfer. However, fully differentiated -like cells with high insulin production and 
glucose responsibility comparable to -cells are not yet available. Further studies on 
-cell differentiation are expected to solve this problem. Among various cell sources, 
pancreas-derived somatic cells might be most promising since even highly proliferative 
MSC-like cells isolated from pancreas express several pancreas-specific genes 
suggesting that they stay at certain stage on the way to -cell differentiation.  
 BAP that enables islet allo- and xeno-transplantation without immune suppression is 
a promising therapeutic approach for T1DM. Micro-encapsulated porcine islets are 
already used in clinical trials and, perhaps replace islet transplantation in the near 
future. Some types of BAP such as macro-encapsulation are also useful to keep 
transplanted cells to be enclosed for possible need of retrieval. Therefore, early clinical 
applications of artificially generated -like cells, especially those from ESCs or iPS cells, 
will be considered in combination of retrievable BAP.  
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 Schematic over view of pancreas development and important transcription factors 
involved in this process during embryogenesis (modified from our previous review 4)).  
 
Fig. 2 
 Schematic relationship and transdifferentiation between pancreatic cell types during 
regeneration process or in duct-ligated lobes.  
 
Fig. 3 
 Schematic figure of bioartificial pancreas.  
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